Compare RVLV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | IMTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2018 | 2020 |
| Metric | RVLV | IMTX |
|---|---|---|
| Price | $22.79 | $6.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $30.85 | $17.26 |
| AVG Volume (30 Days) | 612.7K | ★ 855.3K |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.64 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $13.31 | N/A |
| Revenue Next Year | $9.03 | N/A |
| P/E Ratio | $50.48 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $6.73 |
| 52 Week High | $31.68 | $12.41 |
| Indicator | RVLV | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 28.56 |
| Support Level | $22.47 | N/A |
| Resistance Level | $26.97 | $10.08 |
| Average True Range (ATR) | 0.70 | 0.42 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 72.84 | 3.19 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.